ICOS and neoplasm: He et al. performed scRNA-seq on sorted hepatic ILCs from human patients with HCC and found that targeting inducible T-cell costimulator (ICOS) and its downstream effector HSP70 in ILC2s suppressed tumor growth and remodeled the immunosuppressive tumor microenvironment [174].